Clinical Trial Update: Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema [Phase 2]

View source ↗

Summary

Phase 2 trial comparing intravitreal bevacizumab (Avastin) with intravitreal dexamethasone (Ozurdex) for persistent diabetic macular edema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy

Drugs mentioned

• Avastin (bevacizumab) (bevacizumab)
• Ozurdex (dexamethasone intravitreal implant)

Snippet

Sponsor: University of Sydney | Conditions: Diabetic Retinopathy, Macular Edema | Phase 2 | Status: COMPLETED